Relationships of emerging biomarkers of cancer cachexia with quality of life, appetite, and cachexia

Show simple item record

dc.contributor.author Lipshitz, Melanie
dc.contributor.author Visser, J.
dc.contributor.author Anderson, Ronald
dc.contributor.author Nel, D.G.
dc.contributor.author Smit, T.G. (Theunis)
dc.contributor.author Steel, Helen C.
dc.contributor.author Rapoport, Bernardo Leon
dc.date.accessioned 2024-05-28T06:51:15Z
dc.date.available 2024-05-28T06:51:15Z
dc.date.issued 2024-05
dc.description DATA AVAILABILITY : The data that support the findings of this study and related study tools are available from the corresponding author, Melanie Lipshitz (melanielevydietcian@gmail.com), upon reasonable request. en_US
dc.description SUPPLEMENTARY MATERIAL : FIGURE S1. Functional assessment of anorexia / cachexia therapy (FAACTA/CS-12) categories. FIGURE S2. Cachexia categories for cases and controls. TABLE S1. European organisation for the research and treatment of cancer quality of life–C30 questionnaire (EORTC QLQ-C30) scores. en_US
dc.description.abstract PURPOSE : Quality of life (QoL), appetite, cachexia, and biomarkers [albumin, hemoglobin (Hb), neutrophils, lymphocytes, platelets, C-reactive protein (CRP), tumor necrosis factor alpha (TNFα), interleukin 6 (IL-6), interleukin 8 (IL-8), C-X-C motif chemokine ligand 5 (CXCL5) and citrullinated histoneH3 (H3Cit)] were compared for 40 cases with advanced cancer and 40 healthy controls. Baseline differences and significant relationships were explored for biomarkers with QoL, appetite, and cachexia. METHODS : In a prospective case–control, age and sex matched study, the European Organisation for the Research and Treatment of Cancer Quality of Life–C30 questionnaire (EORTC-QLQ-C30) for QoL, the Functional Assessment of Anorexia and Cachexia Therapy assessment (FAACT A/CS-12) for appetite, and a five-factor cachexia assessment tool for cachexia assessment were performed. Routine hematological measurements and blood chemistry analyses together with ELISA procedures and a Multiplex® bead array platform, were used for biomarker analysis. Descriptive statistics and regression analyses were undertaken. P < 0.05 defined statistical significance. RESULTS : Global health status (QL-G), functional scales (QL-FS), and symptom scales (QL-SS) differed for cases and controls (p < 0.01). In cases, differences were observed for QL-G (p < 0.01), QL-FS (p < 0.01), and QL-SS (p = 0.01) compared to standardized references values. FAACT A/CS-12 scores differed significantly between cases and controls (p < 0.01) and 30% of cases scored “poor” appetites. Cachexia was present in 60% of cases. Albumin, lymphocytes, platelets, Hb, platelet to lymphocyte ratio (PLR), systemic immune-inflammation index (SII), CRP, TNFα, all at p < 0.01, neutrophil to lymphocyte ratio (NLR) (p = 0.02), IL-6 (p < 0.04), and IL-8 (p = 0.02) differed significantly between cases and controls. No difference was found for CXCL5 or H3Cit. Albumin NLR, Hb, PLR, SII, TNFα, IL-8, and CRP showed significant relationships with all aspects of QoL. QL-FS was significantly related to CXCL5 (p = 0.04), significant relationships with FAACT A/CS-12 included: NLR (p = 0.002), Hb (p < 0.001), and PLR (p < 0.01). NLR, PLR, SII, TNFα, IL-6, IL-8, and CRP correlated positively to cachexia and albumin while Hb and lymphocyte count correlated negatively to cachexia. CONCLUSION : CXCL5 and H3Cit were not reliable biomarkers for cancer cachexia, nor significantly related to QoL, appetite or cachexia. Albumin, NLR, Hb, PLR, SII, TNFα, IL-8, and CRP were reliable indicators of QoL, appetite, and cachexia. Future research should include other novel biomarkers namely growth differentiation factor-15 (GDF-15), fibroblast growth factor 21 (FGF-21), fractakline, interferon gamma (IFN-y), IL-16, macrophage colony stimulating factor (M-CSF), and macrophage procoagulant–inducing factor (MPIF). en_US
dc.description.department Immunology en_US
dc.description.librarian hj2024 en_US
dc.description.sdg SDG-03:Good heatlh and well-being en_US
dc.description.sponsorship Open access funding provided by Stellenbosch University. Partial financial support was received from the Harry Crossly Foundation. en_US
dc.description.uri https://www.springer.com/journal/520 en_US
dc.identifier.citation Lipshitz, M., Visser, J., Anderson, R. et al. Relationships of emerging biomarkers of cancer cachexia with quality of life, appetite, and cachexia. Supportive Care in Cancer 32, 349 (2024). https://doi.org/10.1007/s00520-024-08549-5. en_US
dc.identifier.issn 0941-4355 (print)
dc.identifier.issn 1433-7339 (online)
dc.identifier.other 10.1007/s00520-024-08549-5
dc.identifier.uri http://hdl.handle.net/2263/96260
dc.language.iso en en_US
dc.publisher Springer en_US
dc.rights © The Author(s) 2024. Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License. en_US
dc.subject Quality of life (QoL) en_US
dc.subject Anorexia en_US
dc.subject Appetite en_US
dc.subject Biomarkers en_US
dc.subject Cachexia en_US
dc.subject SDG-03: Good health and well-being en_US
dc.title Relationships of emerging biomarkers of cancer cachexia with quality of life, appetite, and cachexia en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record